NORDIC NANOVECTOR NK 0,20 WKN: A1H64K ISIN: NO0010597883 Kürzel: 8NN Forum: Aktien Thema: Hauptdiskussion

... zwei sehr feine Meldungen in letzter Zeit und seit knapp 3 Monaten ist der Chart umgeschwenkt 👌🏼

... heute Ausschüttung zusätzlicher Aktien. Und es steigt sogar 😌

... tja, tröpfelt leider wieder mal kontinuierlich ab der Kurs.

... wäre fein, wenn noch eine vertrauensbildende fortschrittliche Ansage käme und der Wert die 3 € auf lange Sicht halten würde.

🚀🚀

... immerhin die 3 € gestreift 😴

... wäre ein feines Zeichen, wenn sich Nordic über der 3€-Marke stabilisieren könnte.

... das hier noch mal Bewegung rein kommt. Schon sehr lahm der Kurs im letzten Jahr. Aber eben Biotech. Hopp oder Topp. Aussichten scheinen ja ganz gut. Aber erst die Studien im Sommer werden wohl zeigen, wie stark die Substanz ist.

👌🏼

Ist hier noch jemand investiert außer mir?

Ich warte mal bis Freitag und am Wochenende wird ne Order für Montag gesetzt. Zeit zum nachkaufen

Haben jetzt alle ihre Gewinne eingefahren nach den guten News? :D finance.yahoo.com/news/nordic-nanovector-asa-results-fourth-063700451.html 2016 was a very successful year for Nordic Nanovector. We achieved important milestones with regard to the clinical development of Betalutin®, progressed with our preclinical candidates and build the foundation of R&D innovation and expertise for the development of a pipeline of novel targeted therapies for major haematological cancers. The successful completion of a NOK 499 million private placement in December was a key event that will enable the company to work towards its broader long-term ambition. With its strengthened financial position, Nordic Nanovector aims at maximizing the value of its novel targeted biopharmaceutical candidates (Betalutin®, alone and in combination with rituximab, and the chimeric anti-CD37 ARC) across all stages of follicular lymphoma (FL) and other major haematological cancer indications. The company intends to prepare for the commercialisation of Betalutin®, and to selectively extend its pipeline leveraging internal and external innovation and expertise in ARCs and ADCs. The company's confidence in Betalutin® in 3rd line FL was confirmed during the fourth quarter 2016. On the basis of recommendations from the trial's Safety Review Committee, a new, higher dosing regimen is being tested in the Lymrit 37-01 trial. Patient recruitment into Arm 4 of the study is on track to enable the selection of an optimal dosing regimen for the pivotal Phase 2 PARADIGME trial, which is planned to start in the second half of 2017. Updated results from the trial presented at ASH 2016 in December continue to support the promising clinical profile of Betalutin® in 3rd line FL.

Ich hoffe ja das wenn sie gekauft werden, es wieder mal die Chinesen sind. According to Nasdaq, healthcare is one of the fastest-growing sectors in China. By 2020, spending is expected to jump from $350 billion to nearly $1 trillion.

Interessant aber hat halt schon einen ganz schönen Anstieg hinter sich

Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma (NHL) candidate Betalutin. Costa claimed the level of interest in the asset is growing as clinical data accumulates, triggering a double-digit jump in Nanovector’s stock price. Nanovector is now up 670% over the past year. The sharp rise covers a period in which Nanovector has bounced back from a filing-delaying R&D rejig and cases of reversible thrombocytopenia and neutropenia to advanced to the cusp of a pivotal study of its CD37-targeting antibody-radionuclide conjugate. Along the way, Nanovector has released data from its phase 1/2 trial, spurring the interest of investors and, according to Costa, the attention of possible partners and buyers. “We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that's for sure,” Costa told Reuters. Nanovector is up more than 10% this week on the strength of the comment, although at this stage Costa is yet to commit to seeking a buyer, let alone find a company willing to meet the asking price. Pushing ahead with development and potentially commercialization of Betalutin solo or in a partnership are both still options. “[We will be] opportunistic about this,” Costa said. The task of deciding the best path forward will become more of a priority if Betalutin can clear the clinical hurdles it faces. With the phase 1/2 trial reporting overall and complete response rates of 63% and 29% in 35 heavily pretreated patients with relapsed NHL last year, the asset is on the cusp of advancing to the next stage of development. Nanovector raised NOK 499 million ($60 million) to fund development late last year, 20 months after it pulled off a NOK 575 million IPO, one of the larger biotech listings seen in Europe in 2015. Those financings have set Nanovector up to embark on a development path it sees leading to a filing for FDA approval in third-line follicular lymphoma in the first half of 2019 and have the drug on the market before the decade is over. "Our timeline is based on the assumption that the FDA will grant us a breakthrough therapy designation and accelerated approval,” Costa said.

Norwegian biotech newcomer Nordic Nanovector (NANOV.OL), which seeks ways to treat blood-related cancers, says other companies are showing interest in buying the firm. "We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that's for sure," chief executive officer Luigi Costa told Reuters. While Nanovector, founded in 2009 and listed on Oslo's stock market in 2015, may eventually be bought, it could also launch drugs independently or through partnership, Costa said, adding the firm will be "opportunistic about this". Its shares rose 6.7 percent in Oslo following the comments. Nanovector is currently preparing a final test phase for its Betalutin drug candidate, a treatment for Non-Hodgkin Lymphoma (NHL) designed to attach itself to tumors in a novel way before killing them with a dose of radiation. If successful, the drug will be filed for U.S. Food and Drug Administration (FDA) approval in two years' time. The company says it can have a final product on the market by the end of 2019.